Status:
COMPLETED
Effects of Losartan on Insulin Sensitivity and Secretion in Type 2 Diabetes and Nephropathy
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Conditions:
Type 2 Diabetes
Diabetic Nephropathy
Eligibility:
All Genders
17+ years
Phase:
NA
Brief Summary
Angiotensin type-1 receptor (AT1R) blockers (ARBs) have been recognized recently as regulators of glucose and lipid metabolism in adipocytes and adipose tissue.Moreover telmisartan and irbesartan have...
Detailed Description
Angiotensin II (AngII), the main effector peptide of the rennin-angiotensin system (RAS), is implicated in the development of vascular, cardiac, and renal pathologies. Several lines of evidence have s...
Eligibility Criteria
Inclusion
- Fasting plasma glucose (FPG) level of 3.3-9.0mmol/L
- 2h plasma glucose level of 7.5-13 mmol/L
- Body mass index (BMI) of 22 kg/m2
- Two occasions of a ratio of urinary albumin to urinary creatinine≥300 or 24 hours urinary protein concentration is \>150mg.
- Informed consent
Exclusion
- Type1 diabetes or nondiabetic renal disease
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
End Date :
July 1 2006
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00361023
Start Date
January 1 2006
End Date
July 1 2006
Last Update
August 7 2006
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.